Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This target refers to a predicted long non-coding RNA transcript named "novel transcript, antisense to C18orf34," located on chromosome 18 and annotated as ENSG00000263765 (LOC105372058). It is transcribed in antisense orientation to the C18orf34 gene, which encodes a protein called coiled-coil domain containing 178 (CCDC178)[5]. However, there is no experimental evidence for protein-coding capability, biological function, clinical disease association, or therapeutic relevance for this antisense transcript. It likely plays a regulatory role at the RNA level, but such roles remain uncharacterized. There are no drugs, biomarkers, or safety concerns associated with this transcript. The designation of this locus as a therapeutic target is incorrect; it should not be considered a clinically relevant molecule at this time.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel antisense transcript to chromosome 18 open reading frame 34 (ENSG00000263765 (LOC105372058)).